De novo malignancies in renal transplant recipients: Experience at a single center with 1882 transplant patients over 39 yr

Clinical Transplantation

Volumn 27, Issue 1, 2013, Pages

  Apel, Hendrik ^a   Walschburger Zorn, Karin ^a   Häberle, Lothar ^a,b   Wach, Sven ^a   Engehausen, Dirk G ^a   Wullich, Bernd ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Immunosuppression; Incidence; Kidney transplantation; Neoplasms

Indexed keywords

CYCLOSPORIN A;

ADOLESCENT; ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CHILD; DIGESTIVE SYSTEM CANCER; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; POSTTRANSPLANT MALIGNANCY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SKIN CANCER; SQUAMOUS CELL CARCINOMA; URINARY TRACT CANCER;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; INCIDENCE; INFANT; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84873087705     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12050     Document Type: Article

References (26)

1. Rigg KM. Renal transplantation: current status, complications and prevention. J Antimicrob Chemother 1995: 36(Suppl B): 51.
2. Wong G, Chapman JR. Cancers after renal transplantation. Transplant Rev (Orlando) 2008: 22: 141.
3. Danpanich E, Kasiske BL. Risk factors for cancer in renal transplant recipients. Transplantation 1999: 68: 1859.
4. Penn I. Posttransplant malignancies. Transplant Proc 1999: 31: 1260.
5. Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther 2000: 7: 147.
6. ANZDATA. Australia and New Zealand Dialysis and Transplant Registry. Available at: http://www.anzdata.org.au. Accessed July 20, 2011.
7. Collaborative Transplant Study. University of Heidelberg. Available at: http://www.ctstransplant.org. Accessed July 20, 2011.
8. Melchior S, Franzaring L, Shardan A et al. Urological de novo malignancy after kidney transplantation: a case for the urologist. J Urol 2011: 185: 428.
9. Vegso G, Toth M, Hidvegi M et al. Malignancies after renal transplantation during 33 years at a single center. Pathol Oncol Res 2007: 13: 63.
10. Krebs in Deutschland 2005/2006. Häufigkeiten und Trends. 7. ed. Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Berlin, 2010.
11. Greenland S, Rothman KJ, Lash TL. Measures of effect and measures of association. In: Rothman KJ, Greenland S, Lash TL eds. Modern Epidemiology, 3rd edn. Philadelphia: Lippincott, Wiliams & Wilkins, 2008, Chapter 4: 51.
12. Kasiske BL, Snyder JJ, Gilbertson DT et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004: 4: 905.
13. Birkeland SA. De novo cancers complicating renal transplantation: experience in the Nordic countries. Ann Transplant 1997: 2: 22.
14. Sheil AG. Cancer after transplantation. World J Surg 1986: 10: 389.
15. Kauffman HM, Cherikh WS, McBride MA et al. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 2006: 19: 607.
16. Birkeland SA, Storm HH, Lamm LU et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995: 60: 183.
17. Vajdic CM, McDonald SP, McCredie MR et al. Cancer incidence before and after kidney transplantation. JAMA 2006: 296: 2823.
18. Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant 2007: 22(Suppl 1): i4.
19. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998: 351: 623.
20. Kehinde EO, Petermann A, Morgan JD et al. Triple therapy and incidence of de novo cancer in renal transplant recipients. Br J Surg 1994: 81: 985.
21. Tremblay F, Fernandes M, Habbab F et al. Malignancy after renal transplantation: incidence and role of type of immunosuppression. Ann Surg Oncol 2002: 9: 785.
22. Penn I. Cancers in cyclosporine-treated vs azathioprine-treated patients. Transplant Proc 1996: 28: 876.
23. Jonas S, Rayes N, Neumann U et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997: 80: 1141.
24. Berardinelli L, Messa PG, Pozzoli E et al. Malignancies in 2, 753 kidney recipients transplanted during a 39-year experience. Transplant Proc 2009: 41: 1231.
25. Kauffman HM, Cherikh WS, Cheng Y et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005: 80: 883.
26. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005: 352: 1317.